DESTINY-PanTumor-02: Trastuzumab Deruxtecan Has Activity Against a Range of HER2-Expressing Solid Tumors

June 7, 2023 6:55 am

Key Points:

  • Interim results of the phase 2 trial DESTINY-PanTumor-02 show that T-DXd has broad activity across tumor types and a toxicity profile consistent with previous studies.
  • T-DXd had the lowest activity in pancreatic cancer, and this cohort was stopped
Read more

Olaparib-durvalumab regimen prolongs PFS for certain women with advanced ovarian cancer

June 3, 2023 7:02 am

Key takeaways:

  • Researchers reported statistically significant improvement in median PFS with the combination added to standard of care in non-BRCA-mutated disease.
  • The relative contribution of durvalumab requires further study.

 

CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab … Read more

Quintuple Regimen Prolongs PFS in Advanced, High-Grade Epithelial Ovarian Cancer +/- BRCA Mutations

April 5, 2023 4:55 pm

by Nichole Tucker

The DUO-O press release went out on 4/5/2023. It suggests that adding immunotherapy to PARP inhibitor maintenance therapy for newly diagnosed ovarian cancer patients that have finished first-line platinum treatment may be beneficial. We are eagerly awaiting Read more

Neoadjuvant olaparib feasible for women with germline-mutant ovarian cancer

March 27, 2023 9:13 am

by Devin McLaughlin

Neoadjuvant therapy with olaparib showed feasibility for women with germline-mutant ovarian cancer, according to results of the NOW trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Researchers observed favorable surgical outcomes — even … Read more

Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer

March 27, 2023 9:11 am

by Jason Harris

Botensilimab (AGEN1181) in combination with balstilimab (AGEN2034) induced durable responses in patients with resistant/refractory ovarian cancer, according to findings from the phase 1 C-800 study (NCT03860272) presented at the 2023 SGO Annual Meeting on Women’s Cancer.1Read more

Adding HIPEC to Cytoreductive Surgery Does Not Impact HRQOL in Ovarian Cancer

March 25, 2023 9:47 am

by Hayley Virgil

Vadim Gushchin, MD, says that treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of negatively impacting health-related quality of life in ovarian cancer.

Combining hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery

Read more

Machine learning model builds on imaging methods to better detect ovarian lesions

November 29, 2022 11:37 am
by Beth Miller
(From left) The top row shows an ultrasound image of a malignant lesion, the blood oxygen saturation, and hemoglobin concentration. The bottom row is an ultrasound image of a benign lesion, the blood oxygen saturation, and hemoglobin
Read more

Ovarian cancer surveillance results in earlier diagnosis for women with faulty BRCA genes who want to defer surgery

November 1, 2022 4:17 pm

by British Medical Journal

Regularly monitoring women with faulty BRCA genes that make them highly susceptible to ovarian cancer results in earlier stage diagnosis in those who want to defer preventive surgery, finds research published online in the Journal of Read more

Insurance Type Linked With Disparities in the Treatment of Gynecologic Cancer

October 14, 2022 10:36 am

by Jordyn Sava

In the interview with Targeted Oncology, Anna Jo Bodurtha Smith, MD, discusses the effects various insurance types have on the quality of care of patients with gynecologic cancers.Whether a patient with gynecologic cancer has insurance or is … Read more

Study could help recommend the best treatment for women with early-stage mucinous ovarian cancer

October 12, 2022 1:23 pm

by Emily Henderson, B.Sc.

A global study into mucinous ovarian cancer could help oncologists recommend the best treatment for women who are diagnosed early with the condition.

By looking down a microscope for two different ‘patterns of invasion’ – the … Read more

Ovarian Cancer Detection Takes a Step Forward

September 12, 2022 1:45 pm

A new type of technology can capture stray ovarian cancer cells from a simple blood test and successfully predict cancer in people who have a lesion or cyst in the pelvic region, according to a new study by a Wilmot … Read more

Nonselective Beta-Blockers May Improve Outcomes in Ovarian Cancer

August 29, 2022 2:19 pm

by Charles Bankhead

Women with cardiovascular conditions (CVCs) and ovarian cancer had better 2-year survival if they received a nonselective beta blocker (NSBB) at or around the time of cancer surgery, a review of medical records showed.

Two-year postoperative survival … Read more

Understanding the genetic testing-related information needs of ovarian cancer patients

July 29, 2022 11:45 am

Reviewed by Emily Henderson, B.Sc.

JMIR Publications recently published “Understanding the Information Needs of Patients With Ovarian Cancer Regarding Genetic Testing to Inform Intervention Design: Interview Study” in JMIR Cancer, which reported that experts in gynecological cancer care recommend that … Read more

Researchers Use US to Predict Ovarian Cancer

March 22, 2022 11:13 am

Approach can help radiologists in a busy clinical practice assess lesions more quickly

The appearance of ovarian lesions on ultrasound is an effective predictor of cancer risk that can help women avoid unnecessary surgery, according to a new study published … Read more

Intraperitoneal Carboplatin Plus Paclitaxel Improves PFS in Ovarian Cancer, Yet OS Results Remain Unchanged Vs IV Chemo

March 20, 2022 10:18 am

by Gina Mauro

The iPocc trial indicated that patients with ovarian cancer experienced an improvement in progression-free survival when treated with intraperitoneal carboplatin plus paclitaxel compared with intravenous chemotherapy, but this benefit did not translate to overall survival.

The use

Read more

Paclitaxel Plus Carboplatin Is Reportedly Non-Inferior to Paclitaxel and Ifosfamide in Uterine Carcinosarcoma

January 13, 2022 8:49 am

by Ariana Pelosci

Findings from a phase 3 study indicated that patients with uterine carcinosarcoma treated with paclitaxel and carboplatin experienced a better progression-free survival and non-inferior duration of overall survival vs paclitaxel plus ifosfamide.

A combination regimen of paclitaxel

Read more

Not-So-Silent Early-Stage Ovarian Cancer

January 6, 2022 11:11 am

by Charles Bankhead

— More than 70% of patients reported one or more symptoms prior to diagnosis

More than 70% of women with high-risk early ovarian cancer had one or more symptoms of underlying disease, most often abdominal or pelvic … Read more

Why Black women with ovarian cancer require greater focus

December 15, 2021 9:55 am

by Sophia George

Providing equal access to care will not by itself equalize outcomes between Black and white women.

Women from the African diaspora are disproportionately affected by high-grade and aggressive ovarian tumours. In the United States, mortality due to … Read more

FDA approves pioneering drug for ovarian cancer surgery

November 29, 2021 10:11 am

by Steve Tally

Purdue-developed imaging drug allowed surgeons to find additional cancer lesions

Left image: A drug used for fluorescent imaging during ovarian cancer surgeries, which was just approved by the FDA, lights up cancer cells “like stars against a Read more

A Better Option for Preserving Fertility in Gynecologic Cancer Patients?

October 19, 2021 12:00 am

— In vitro maturation can result in both embryos and oocyte vitrification, researcher says

by Amanda D’Ambrosio

In vitro maturation of immature eggs may be an effective method of fertility preservation for patients with gynecologic cancers, according to a prospective … Read more